HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

New Horizon Health (6606.HK) - Still Has a Long Way to Go

Pre-IPO Zhaoke Ophthalmology Pharmaceutical - It Remains to Be Seen How to Find Its Way Out

2021 High Conviction - Investment Opportunities in China Healthcare Industry

Pre-IPO Harbour Biomed (2142.HK) - Don't Ignore The "Hidden Value"

Pre-IPO Edding Group - Strong Core Products but Still Have Concerns

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

New Horizon Health  / Equity Capital Markets

<p style="text-align: justify;">On November 10<sup>th</sup> 2020, <a href="https://www.smartkarma.com/entities/new-horizon-health-limited" target="_blank" data-smartkarma-citation="entities:31039:1" rel="noopener">New Horizon Health (NHH HK)</a> filed the application to list on the Hong Kong stock exchange. Founded in November 2015, the Company focuses on early screening and detection services for high-incidence cancer homes in China, with products covering colorectal cancer, cervical cancer, stomach cancer, lung cancer, liver cancer and other fields. Although the market prospect is very good, there are still some concerns.</p>

On November 10th 2020, New Horizon Health (NHH HK) filed the application to list on the Hong Kong stock exchange. Founded in November 2015, the Company focuses on early screening and detection services for high-incidence cancer homes in China, with products covering colorectal cancer, cervical cancer, stomach cancer, lung cancer, liver cancer and other fields. Although the market prospect is very good, there are still some concerns.

Pre-IPO New Horizon Health (NHH.HK) - Here Are the Concerns